Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27787948 | 0.98 | MAPK1 (0.61) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL397773 | 0.88 | MAPK1 (0.77) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL11004175 | 0.88 | MEN1 (0.64) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL27927073 | 0.86 | TSHR (0.64) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL6392737 | 0.86 | MAPK1 (0.59) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL11335468 | 0.85 | L3MBTL1 (0.56) | MAPK1ALDH1A1TDP1L3MBTL1HSD17B10 | |
| SCHEMBL23682559 | 0.85 | TDP1 (0.54) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL6565464 | 0.82 | ALDH1A1 (0.51) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL2329868 | 0.82 | L3MBTL1 (0.51) | MAPK1ALDH1A1TDP1L3MBTL1HSD17B10 | |
| SCHEMBL5186760 | 0.82 | ALDH1A1 (0.57) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173803-B2 | Supramolecular scaffolds and methods of making the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100041880-A1 | Supramolecular Scaffolds and Methods of Making the Same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600701-A | Arylsulfonamide derivatives and methods of use thereof | WYETH CORP (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1789050-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006016278-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY, LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | MAPK1 1902/4885ALDH1A1 612/4885TDP1 1150/4885 |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MAPK1 1634/4885ALDH1A1 687/4885TDP1 367/4885 |
| US-20100041880-A1 | Supramolecular Scaffolds and Methods of Making the Same | BLM, TBXAS1, TOP2B | MAPK1 1719/4885ALDH1A1 1363/4885TDP1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.